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Adenosine receptor expression and function in rat striatal
cholinergic interneurons
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1Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QJ; 2Parke-Davis, Cambridge
University Forvie Site, Robinson Way, Cambridge, CB2 2QB and 3The Sanger Centre, Wellcome Genome Campus, Hinxton,
Cambridge, CB10 1SA
1 Cholinergic neurons were identified in rat striatal slices by their size, membrane properties,
sensitivity to the NK1 receptor agonist (Sar
9, Met(O2)
11) Substance P, and expression of choline
acetyltransferase mRNA. A1 receptor mRNA was detected in 60% of the neurons analysed, and A2A
receptor mRNA in 67% (n=15).
2 The A1 receptor agonist R-N
6-(2-phenylisopropyl)adenosine (R-PIA) hyperpolarized cholinergic
neurons in a concentration dependent manner sensitive to the A1 antagonist 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX, 100 nM).
3 In dual stimulus experiments, the A2A receptor antagonist 8-(3-chlorostyryl)caeine (CSC,
500 nM) decreased release of [3H]-acetylcholine from striatal slices (S2/S1 0.78+0.07 versus
0.95+0.05 in control), as did adenosine deaminase (S2/S1 ratio 0.69+0.05), whereas the A1 receptor
antagonist DPCPX (100 nM) had no eect (S2/S1 1.05+0.14).
4 In the presence of adenosine deaminase the adenosine A2A receptor agonist 2-p-((carboxyethyl)-
phenylethylamino)-5’-N-ethylcarboxamidoadenosine (CGS21680, 10 nM) increased release (S2/S1
ratio 1.03+0.05 versus 0.88+0.05 in control), an eect blocked by the antagonist CSC (500 nM, S2/
S1 0.68+0.05, versus 0.73+0.08 with CSC alone). The combined superfusion of bicuculline (10 mM),
saclofen (1 mM) and naloxone (10 mM) had no eect on the stimulation by CGS21680 (S2/S1 ratio
0.99+0.04).
5 The A1 receptor agonist R-PIA (100 nM) inhibited the release of [
3H]-acetylcholine (S2/S1 ratio
0.70+0.03), an eect blocked by DPCPX (S2/S1 ratio 1.06+0.07).
6 It is concluded that both A1 and A2A receptors are expressed on striatal cholinergic neurons
where they are functionally active.
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Abbreviations: CGS21680, 2-p-((carboxyethyl)phenylethylamino)-5,-N-ethylcarboxy amidoadenosine; CSC, 8-(3-chlorostyryl)-
caeine; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; TPEA PCR, 3’ end amplification polymerase chain
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Introduction
Adenosine A2A receptor antagonists represent a class of non
dopamine related drugs which are being tested for their ecacy
in the treatment of Parkinson’s Disease (Richardson et al.,
1997). However the mechanism of action of such drugs is
unclear, and in particular the possible involvement of such
receptors on striatal cholinergic interneurons is debatable
(Fredholm & Svenningsson, 1998; Richardson et al., 1998).
Indeed, there are a number of discrepancies in the literature
relating to the expression and function of adenosine A1 and
A2A receptors in these neurons.
The adenosine A1 receptor has been shown to inhibit ACh
release from striatal cholinergic nerve terminals (Brown et al.,
1990), and the adenosine A2A receptor has been shown to
stimulate acetylcholine release from striatal synaptosomes
(Brown et al., 1990; Kurokawa et al., 1994; Kirk &
Richardson, 1994; Gubitz et al., 1996). However, A2A receptor
agonists have also been reported to have no eect on
acetylcholine release from striatal slices, other than in the
presence of dopamine (Jin et al., 1993; Jin & Fredholm, 1997).
In addition few molecular studies have confirmed the
expression of A1 receptor mRNA in these cells (Reppert et
al., 1991; Rivkees et al., 1995; Dixon et al., 1996), and the
majority of attempts to detect A2A receptor mRNA expression
in striatal cholinergic neurons have failed (Schimann et al.,
1991; Schimann & Vanderhaeghen, 1993; Fink et al., 1992;
Svenningsson et al., 1997). Only one in situ hybridization study
has shown mRNA encoding the A2A receptor to be expressed
in some large (presumably cholinergic) striatal neurons at low
abundance (Dixon et al., 1996).
Since the discrepancies concerning adenosine receptor
mRNA expression in striatal cholinergic neurons may have
been due to diering sensitivities of the techniques used, we
have employed a highly sensitive single cell RT–PCR method
to examine A1 and A2A receptor expression in these cells. In
addition it is possible that the debate over the potential
functional relevance of the A2A receptor in these cells was a
consequence of the dierent in vitro preparations (synapto-
somes and slices) used. We have therefore also examined the
ability of A1 and A2A receptor agonists to regulate acetylcho-
line release from rat brain striatal slices.*Author for correspondence; E-mail: pjr1001@cam.ac.uk




Three hundred mm thick coronal slices (male Sprague Dawley
rats, 14 – 28 days old) were prepared using a vibratome, and
bathed in aCSF of the following composition (mM); NaCl 125,
NaHCO3 25, glucose 10, KCl 2.5, NaH2PO4 1.25, CaCl2 2,
MgCl2 1, bubbled with 95% O2 and 5% CO2 gas mixture, and
viewed with a Zeiss Axioskop microscope (Carl Zeiss Ltd.,
Welwyn Garden City, U.K.) fitted with a x64 water-immersion
objective as previously described (Lee et al., 1998). The
electrode buer contained (in mM): K gluconate 120, NaCl
10, MgCl2 2, EGTA 0.5, HEPES 10, Na2ATP 4, Na2GTP 0.3,
pH adjusted to 7.2 with KOH. In addition 0.5 mg ml71
glycogen (Boehringer) and RNase inhibitor (Pharmacia,
0.1 u ml71 were included to facilitate the harvesting of RNA
from the cells. All solutions were made up in diethyl
pyrocarbonate treated water (to inactivate RNases). Borosili-
cate recording electrodes were baked (2 h, 2508C) before being
pulled to a resistance of between 3 and 5 MO. Electro-
physiological signals were detected using an Axopatch-1D
patch-clamp amplifier in the current clamp configuration and
were recorded onto digital audiotape for later production.
Membrane signals were filtered at 1 kHz and were digitized at
5 kHz through a Digidata 1200A/D converter using pClamp
6.0 software (Axon Instruments Inc, CA, U.S.A.).
The cytoplasm from large cells (430 mm in one dimension)
was gently aspirated under visual control into a patch-clamp
recording electrode until at least 40% of the somatic cytoplasm
had been collected. The electrode was then withdrawn from the
cell to form an outside-out patch, or a nucleated patch, to
prevent contamination on subsequent withdrawal from the
slice. The contents of the electrode were forced into a
microtube and reverse transcribed, subjected to 3’ cDNA
amplification (TPEA–PCR), and 6% of the product used in
each gene specific PCR reaction as described in Dixon et al.
(1998) with the following modifications. Four defined
pentameric sequences were present at the 3’ ends of the
second-strand cDNA primers, each primer contained the
following heel sequence at the 5’ end: CTG CAT CTA TCT
AAT GCT CC. The four arbitrary 3’ sequences were:
CGAGA, CGACA, CGTAC and ATGCG. 2.5 pg of each
second strand primer were annealed at 508C to the first strand
cDNA, and second strand cDNA synthesis was performed at
728C for 8 min using Taq DNA polymerase (0.35 units, Perkin
Elmer) at pH 8.3 using 4.5 mM MgCl2 and 0.5 mM dNTPs.
Subsequently, 1 ng of the 5’ and 3’ heel primers were added in
5 ml of PCR buer containing 67 mM Tris HCl (pH 8.3),
4.5 mM MgCl2 0.5 mM dNTPs and 0.16 units of Taq and the
reaction subjected to 10 cycles of 928C (2.5 min, denaturation),
608C (annealing, 1.5 min) and 728C (extension, 1 min),
followed by a final 10 min extension. A further 10 ng of each
heel primer were then added in 20 ml of PCR buer and
subjected to a further 40 rounds of PCR (conditions as before).
The final reaction mixture was then diluted to 100 ml with
10 mM Tris/ 0.1 mM EDTA (pH 8.1), and 6 ml samples used
for subsequent gene specific PCR. Gene specific PCR was
performed as described (Dixon et al., 1998) using the following
primers (accession number, base number): choline acetyltrans-
ferase: forward primer (sequence from Brice et al., 1989,
2134 – 2155 TACTAAGCTCTGTTCCCATCCC, reverse pri-
mer 2303 – 2285, ACCCAGGTTGCTTCCAAAC), adenosine
A1 receptor (Y12519, forward primer 2507 – 2526; reverse
primer 2637 – 2619), adenosine A2A receptor (L08102, forward
primer 1817 – 1835; reverse primer 1980 – 1960), NK1 receptor
(J05097, forward primer 2991 – 3010; reverse primer 3195 –
3176; preproenkephalin (S49491, forward primer 1033 – 1050;
reverse primer 1180 – 1159); preprotachykinin (M34184, for-
ward primer 717 – 735; reverse primer 877 – 85). The genomic
primers recognized two polymorphic repeats: STS ET3
(forward primer: GCCTGCATTCATCTTCATCTGC, re-
verse primer: AAAGGTGGAACTCGCCCGTTT) and STS
RR1023 (forward primer: AGCCTCATCGATGCTCCTGT,
reverse primer: CCAAGAGCTACCTGCACTCC).
All of the gene specific primers used had similar sensitivities,
detecting cDNA derived from as little as 10 pg total whole
brain RNA, while the genomic primers detected as little as
10 pg of rat genomic DNA.
Release experiments
Three hundred mm thick rat striatal slices, prepared as
described above, were labelled with [3H]-choline chloride
(0.2 mM, for 45 min, at 378C) and perfused with aCSF at a
rate of 0.5 ml min71. The superfusion buer contained
hemicholinium-3 (10 mM) to inhibit choline re-uptake. After
an equilibration period of 45 min, samples were collected at
2 min intervals and counted for radioactivity. Release was
stimulated twice in each case by inclusion of 15 mM KCl in the
superfusion buer for 1.5 min. The evoked release for each
stimulus was expressed as a percentage of the total amount of
radiolabel present in the slice at the point at which release was
evoked, and evoked release calculated by subtracting basal
release from total release for each stimulus. Modulation of
release was assessed by changes in the ratio of the [3H]-label
release between two stimuli S1 and S2 (spaced 20 min apart).
In control experiments S1 and S2 both contained 15 mM KCl,
but in test experiments S1 contained KCl whereas S2 contained
KCl plus agonist i.e. CGS 21680 (10 nM) or R-PIA (100 nM).
The receptor antagonists CSC (500 nM), DPCPX (100 nM),
bicuculline (10 mM), saclofen (1 mM) and naloxone (10 mM)
were included in the superfusion buer for 20 min prior to and
during the second stimulus. In some experiments assessing the
role of endogenous adenosine, adenosine deaminase was
present in the superfusion buer 20 min prior to and during
the second stimulus. However in most experiments adenosine
deaminase (I u ml71) was present throughout the superfusion.
The identity of the released [3H]-label during stimulation by
15 mM KCl (in the presence of eserine, 1 mM) was shown to be
60 – 70% acetylcholine by thin layer chromatography (March-
banks, 1968), as previously found in this system (Kirkpatrick
& Richardson, 1993; 1994; Preston et al., 1999). For thin layer
chromatography 0.2 ml samples were collected during super-
fusion (both during stimulation and basal release), 0.1 mmol of
choline and acetylcholine added as carrier, and applied to thin
layer cellulose chromatography plates. The plates were
developed using a mobile phase of butan-1-ol, acetic acid,
water and ethanol (8 : 1 : 3 : 2), and the spots containing choline
and acetylcholine visualized using a spray of 4.5% potassium
iodide, 0.25% platinic chloride in aqueous ethanol
(1 : 1 v v71). The spots were excised and the radioactivity
determined in a liquid scintillation counter. Means+s.e.mean
were calculated and statistical significance assessed using
Student’s t-test.
Results
Cholinergic neurons in striatal slices were identified on the
basis of their size (30 mm diameter), and by their resting
electrophysiological properties on membrane rupture (Kawa-
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guchi 1992; 1993). Thus these cells had a resting membrane
potential of758.6+1.4 mV, and were frequently found to fire
spontaneous action potentials at a rate of 2 – 5 Hz. These
action potentials were associated with a large after hyperpolar-
ization (of 24.1+1.3 mV), as previously observed in inter-
neurons of this type (Kawaguchi 1992; 1993). These cells also
showed a decrease in apparent input resistance on injection of
hyperpolarizing current as reported previously (Jiang & North,
1991), and also depolarized in response to bath application of
the NK1 receptor agonist Sar
9, Met(O2)
11 Substance P, (Bell et
al., 1998). After harvesting the cytoplasmic contents of such
cells, reverse transcription and TPEA–PCR, the expression of
a variety of genes was assessed in gene specific PCR assays. As
shown in Figure 1, the coexpression of choline acetyltransfer-
ase with the A1 receptor was observed in 60%, and the
adenosine A2A receptor in 67% (n=15) of the cells tested. In
contrast PCR primers for preproenkephalin, preprotachykinin
and the genomic sequences tested consistently failed to reveal a
PCR product.
Bath application of the A1 receptor agonist R-PIA to the
superfusion fluid caused a concentration dependent small
hyperpolarization of the large cholinergic neurons. Thus 10
and 100 nM R-PIA had no discernible eect on the resting
membrane properties of these neurons (n=3 for each), 1 mM
R-PIA caused a 3.2+1.1 mV hyperpolarization (n=8 out of
11 cells), and 5 mM R-PIA produced a 3.8+0.5 mV
hyperpolarization (n=5 out of seven cells). The eects of
1 mM R-PIA were retained in the presence of 1 mM TTX (n=4,
3.1+0.5 mV hyperpolarization) and were completely blocked
by preincubation of the slice with the A1 receptor antagonist
DPCPX (100 M, n=3, Figure 2).
The eect of the A1 and A2A receptors on acetylcholine
release from striatal slices evoked by a submaximal concentra-
tion of KCl (15 mM) was investigated. Inclusion of the A1
receptor antagonist (DPCPX, 100 nM) had no significant eect
on the release of [3H]-acetylcholine. In contrast the A2A
receptor antagonist CSC (500 nM) decreased the release
(Figure 3), which suggested the action of endogenous
adenosine within the slice. This was confirmed by inclusion
of adenosine deaminase (1 u ml71) after the first stimulus,
which caused a reduction in the release of acetylcholine in the
second stimulus (Figure 3).
In an attempt to reduce the influence of endogenous
adenosine, adenosine deaminase was included throughout the
superfusion in subsequent experiments. Under these conditions
DPCPX had no significant eect on acetylcholine release,
although the A1 receptor agonist R-PIA significantly inhibited
the release in a DPCPX sensitive manner. In contrast, the
selective agonist CGS 21680 (10 nM) significantly enhanced
release in a CSC sensitive manner (Figure 3). Since the A2A
receptor has been shown to regulate striatal GABA release
from striatopallidal (enkephalin containing) neurons, the eect
of GABA and opioid antagonists was investigated. The
enhancement of acetylcholine release by CGS 21680 was
slightly, but not significantly, reduced by the coadministration
of bicuculline (10 mM), saclofen (1 mM) and naloxone (10 mM,
Figure 3).
Discussion
Striatal cholinergic neurons were identified on the basis of their
morphology, resting electrophysiological responses (Kawagu-
chi, 1992; 1993), response to the NK1 receptor agonist (Sar
9,
Met(O2)
11) Substance P (Bell et al., 1998) and the expression of
mRNAs encoding choline acetyltransferase. In these cells
mRNA encoding the A1 receptor was detected in 60% of the
neurons sampled and the A2A receptor mRNA in 67%. These
cells were shown not only to express the receptor messages but
also functional receptor protein, since the A1 receptor agonist
R-PIA hyperpolarized these cells and inhibited acetylcholine
release, while the A2A receptor agonist CGS21680 increased
Figure 1 Expression of adenosine A1 and A2A receptors in striatal
cholinergic neurons. Cytoplasmic samples from identified cholinergic
neurons were subjected to TPEA–PCR followed by gene specific
PCR. (A) Typical ethidium bromide stained agarose gels showing the
expression of choline acetyltransferase (ChAT), and adenosine A1
and A2A receptors in four cholinergic neurons, but no detection of
genomic DNA by genomic primers 1 and 2, nor of preproenkephalin
(pENK) nor preprotachykinin (PPT) mRNA. (B) Bar plot showing
the expression of these genes in striatal cholinergic neurons, expressed
as per cent of the neurons in which expression of these genes was
detected, n=25 (ChAT, genomic, preproenkephalin, preprotachyki-
nin), n=15 (A1 and A2A receptors).
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acetylcholine release. Although the majority of these choliner-
gic neurons express these receptors, those that were apparently
negative may represent a distinct subpopulation which do not
express these receptors, or alternatively that the mRNAs were
below the level of detection in these cells.
The discrepancy between these results and those obtained
by in situ hybridization is most probably a consequence of the
previously recognised low abundance of A2A receptor mRNA
in striatal cholinergic neurons (Dixon et al., 1996), and the
high sensitivity of this PCR based technique. It is unlikely that
the detection of the adenosine receptors was due to
contamination by other cells or genomic DNA since mRNAs
encoding preproenkephalin and preprotachykinin (two genes
expressed in high abundance in 90% of striatal neurons,
Graybiel, 1990) were not detected in our samples, nor were two
genomic STS sequences. Expression of the A1 receptor is
consistent with some previous in situ hybridization data
(Dixon et al., 1996), and with the reported ability of A1
receptor agonists to inhibit acetylcholine release (Brown et al.,
1990; Jin et al., 1993).
In an attempt to reconcile conflicting reports concerning the
functional eects of adenosine receptors in these cells (Jin et
al., 1993; Jin & Fredholm, 1997; Brown et al., 1990; Kirk &
Richardson, 1994; Kurokawa et al., 1994) we examined the
eect of selective ligands on acetylcholine release in striatal
slices. Adenosine deaminase revealed a tonic endogenous
adenosine tone which increased acetylcholine release, and was
blocked by the presence of the A2A receptor selective
antagonist CSC. The increase in release elicited by CGS21680
was also reversed by CSC, but not by a combination of opioid
and GABA receptor antagonists, suggesting that the A2A
receptor was not acting presynaptically on the GABA and
enkephalin containing striatopallidal recurrent collatetral
nerve terminals (Kirk & Richardson, 1994; Mori et al.,
1996). Since these antagonists were also unable to mimic the
eect of CSC on potassium stimulated release, it is probable
the endogenous tone was also directly exerted on the
cholinergic neuron.
The overall stimulatory action of adenosine contrasts with a
tonic inhibitory eect seen in the slices of Jin et al. (1993) and
Jin & Fredholm (1997). This dierence in the action of
endogenous adenosine between the two preparations may
underlie the diering eects seen with selective agonists, and
could perhaps be explained by dierent degrees of A2A receptor
desensitization during slice preparation.
In conclusion both A1 and A2A receptors are expressed in
striatal cholinergic neurons where they are functionally active.
Figure 2 Whole cell current clamp recording illustrating the eect of
R-PIA on the resting electrophysiological properties of a visually
identified cholinergic interneuron. Bath application of 1 mM R-PIA
produced a reversible hyperpolarization of the neuron which was
associated with the cessation of action potential firing (upper panel).
This eect of R-PIA is maintained in the presence of 1 mM TTX
(middle panel) but is lost in the presence of 100 nM DPCPX (bottom
panel. Note that approximately 20 min time interval is present
between traces.
Figure 3 Adenosine receptor modulation of ACh release from
striatal slices. 3H-ACh release was evoked by two 2 min pulses of
15 mM KCl spaced 20 min apart (S1 and S2) and the S2/S1 ratio are
shown after subtraction of basal release. The agonists CGS21680
(10 nM) and R-PIA (100 nM) were administered during S2 only, while
the antagonists CSC (500 nM), DPCPX (100 nM), bicuculline
(10 mM), saclofen (1 mM) and naloxone (10 mM) were present 20 min
before, and during, S2. Antags: combined administration of bicucul-
line, saclofen and naloxone. (A) Eect of endogenous adenosine.
Results are means+s.e.mean of between four and eight experiments,
each containing duplicates. AdA: adenosine deaminase present in the
superfusion fluid 20 min before and during S2 (1 u ml71); *indicates
significantly dierent from control (P50.05). (B) Eect of adenosine
receptor ligands in the presence of adenosine deaminase. Adenosine
deaminase was present throughout the superfusion of the slices.
Results are means+s.e.mean of between four and eight experiments
each containing duplicates or triplicates. Antagonists: simultaneous
administration of bicuculline (10 mM), saclofen (1 mM) and naloxone
(10 mM) *indicates significantly dierent from control (P50.05),
**indicates significantly dierent from agonist alone (P50.05).
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